Who is on it, and how far along Every drug ChEMBL records acting on PDE4A, by the furthest stage it has reached for any use, coloured by modality.
How to read this Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
Small molecule 23 Protein or peptide 1 Approved10 Apremilast Apremilast SponsorAmgen ModalitySmall molecule ActionInhibitor Open trials30 Roflumilast Roflumilast SponsorAstraZeneca Pharmaceuticals ModalitySmall molecule ActionInhibitor Open trials25 Crisaborole Crisaborole SponsorPfizer ModalitySmall molecule ActionInhibitor Open trials9 Ensifentrine Ensifentrine SponsorMerck & Co. (MSD) ModalitySmall molecule ActionInhibitor Open trials3 Ibudilast Ibudilast SponsorMediciNova ModalitySmall molecule ActionInhibitor Open trials2 Dyphylline Dyphylline SponsorTeva Pharmaceutical Industries ModalitySmall molecule ActionInhibitor Open trials1 Theophylline anhydrous Theophylline anhydrous SponsorOrganon ModalityProtein or peptide ActionInhibitor Open trials1 Amlexanox Amlexanox SponsorULURU ModalitySmall molecule ActionInhibitor Open trials0 Flavoxate Flavoxate SponsorJohnson & Johnson ModalitySmall molecule ActionInhibitor Open trials0 Theophylline glycinate Theophylline glycinate SponsorCent Pharmaceuticals ModalitySmall molecule ActionInhibitor Open trials0 Phase 34 Difamilast Difamilast SponsorAcrotech Biopharma ModalitySmall molecule ActionInhibitor Open trials2 Cilomilast Cilomilast SponsorGSK ModalitySmall molecule ActionInhibitor Open trials0 Drotaverine Drotaverine SponsorNot known ModalitySmall molecule ActionInhibitor Open trials0 Tetomilast Tetomilast SponsorOtsuka Pharmaceutical ModalitySmall molecule ActionInhibitor Open trials0 Phase 210 Dovramilast Dovramilast SponsorAmgen ModalitySmall molecule ActionInhibitor Open trials1 GSK-256066 GSK-256066 SponsorGSK ModalitySmall molecule ActionInhibitor Open trials0 HT-0712 HT-0712 SponsorDart NeuroScience, LLC ModalitySmall molecule ActionInhibitor Open trials0 Lotamilast Lotamilast SponsorOrganon ModalitySmall molecule ActionInhibitor Open trials0 MK-0873 MK-0873 SponsorMerck & Co. (MSD) ModalitySmall molecule ActionInhibitor Open trials0 Oglemilast Oglemilast SponsorAbbVie ModalitySmall molecule ActionInhibitor Open trials0 Revamilast Revamilast SponsorGlenmark Pharmaceuticals ModalitySmall molecule ActionInhibitor Open trials0 Rolipram Rolipram SponsorGSK ModalitySmall molecule ActionInhibitor Open trials0 Tofimilast Tofimilast SponsorPfizer ModalitySmall molecule ActionInhibitor Open trials0 Tranimilast Tranimilast SponsorChiesi Farmaceutici ModalitySmall molecule ActionInhibitor Open trials0
Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Phosphodiesterase 4 inhibitor. The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 33 in all, from ClinicalTrials.gov. Trial Drug Phase Status Lead sponsor First posted Roflumilast Cream 0.3% for Moderate to Severe Atopic Dermatitis Roflumilast Phase 3 Recruiting Arcutis Biotherapeutics, Inc. Nov 4, 2026 Comparing the Extent to Which Apremilast is Made Available in the Body After Administration as an Extended-release or Immediate-release Formulation Apremilast Phase 1 Recruiting Amgen Nov 2, 2026 Evaluation of Crisaborole 2% Versus Tacrolimus 0.1% Each Combined With Excimer Light in the Treatment of Stable Non-segmental Facial Vitiligo: a Prospective Randomized Controlled Study. Crisaborole Phase 3 Recruiting Cairo University Oct 29, 2026 Evaluating the Safety and Efficacy of Roflumilast in the Treatment of Nonalcoholic Fatty Liver Disease Patients Roflumilast Phase 2 / Phase 3 Not yet recruiting Tanta University Oct 28, 2026 Efficacy of Crisaborole 2% Ointment Versus Tacrolimus 0.1% Ointment in the Treatment of Intertriginous and/or Anogenital Psoriasis. Crisaborole Phase 3 Not yet recruiting Cairo University Oct 23, 2026 Ensifentrine (MK-5884) Study for the Prevention of Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in Adults With a History of Moderate or Severe Exacerbations While Receiving Standard of Care (SOC) (MK-5884-031/RPL554/ENHANCE-3) Ensifentrine Phase 3 Recruiting Merck Sharp & Dohme LLC Oct 15, 2026 Apremilast Added to Antihistamines in Chronic Urticaria Apremilast Phase 2 Enrolling by invitation Rashid Latif Medical College Sep 30, 2026 Comparative Effectiveness of Roflumilast and Azithromycin in Reducing Exacerbations in Severe Chronic Obstructive Pulmonary Disease ( COPD ) Patients With Chronic Bronchitis Phenotype Roflumilast Phase 4 Not yet recruiting Sidra Aziz Aug 31, 2026 An Open Label Trial to Evaluate Efficacy and Safety of Roflumilast 0.3% Cream for Chronic Plaque and Nail Psoriasis Roflumilast Phase 4 Recruiting Modern Research Associates, PLLC Jul 24, 2026 Safety and Efficacy of Roflumilast Foam 0.3% in Adolescent and Adult Subjects With Hidradenitis Suppurativa Roflumilast Phase 2 Recruiting Harrison Dermatology Jul 8, 2026 Efficacy and Safety of Roflumilast Foam 0.3% in Trial Participants With Seborrheic Dermatitis Roflumilast Phase 3 Recruiting Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. Jul 6, 2026 An Open-label, Single Center Study Evaluating the Safety and Efficacy of Roflumilast Foam 0.3% in Subjects With Cutaneous Adverse Events Due to Checkpoint Inhibitors Roflumilast Phase 2 Not yet recruiting Massachusetts General Hospital Jun 10, 2026 Effect of Roflumilast as Add-On Therapy in Rheumatoid Arthritis Roflumilast Phase 2 Recruiting Horus University Jun 8, 2026 EFFICACY OF ROFLUMILAST IN THE TREATMENT OF FLEXURAL AND/OR GENITAL PSORIASIS: A RANDOMIZED CONTROLLED TRIAL. Apremilast Phase 2 Not yet recruiting Eman Raafat Said Apr 22, 2026 A Randomized Controlled Trial Comparing the Effectiveness and Safety of Topical Tacrolimus 0.03% Versus Crisaborole 2% in Patients With Mild to Moderate Atopic Dermatitis Over 8 Weeks Crisaborole Not applicable Not yet recruiting Foundation University Islamabad Apr 9, 2026 Theophylline, Versus Sumatriptan and Gabapentin in The Treatment of Post-Dural Puncture Headache Theophylline anhydrous Not applicable Recruiting Tanta University Apr 7, 2026 Efficacy of Crisaborole 2% Cream Versus Placebo in Mild to Moderate Atopic Eczema Crisaborole Phase 4 Not yet recruiting Jinnah Postgraduate Medical Centre Feb 27, 2026 Comparative Evaluation of the Safety and Effectiveness of Crisaborole Ointment (2%) Versus Tacrolimus Ointment (0.1%) for the Topical Treatment of Atopic Dermatitis Crisaborole Phase 4 Not yet recruiting Hayat Abad Medical Complex, Peshawar Feb 27, 2026 Methotrexate Versus Apremilast for Pruritus in Psoriasis Apremilast Phase 4 Not yet recruiting Zarmeen Khawar Feb 25, 2026 Apremilast and Adalimumab in Psoriatic Arthritis Patients Apremilast Not applicable Not yet recruiting Tanta University Feb 10, 2026 Evaluation the Topical Apremilast Nanoformulation in Treatment of Localized Plaque Psoriasis Apremilast Not applicable Not yet recruiting Assiut University Jan 26, 2026 Comparative Study of Crisaborole vs. Tacrolimus in Atopic Dermatitis Crisaborole Phase 4 Not yet recruiting Cairo University Jan 26, 2026 Utilization of a Microdevice for Psoriasis and Atopic Dermatitis Apremilast, Crisaborole Phase 4 Not yet recruiting University of California, San Francisco Jan 20, 2026 To Check Comparison of Apremilast and Methotrexate Efficacy in Patients With Moderate to Severe Plaque Psoriasis Presented to Tertiary Care Hospital Apremilast Early phase 1 Recruiting Syeda Sana Zaman Jan 13, 2026 A Phase 3 Trial of OPA-15406 Foam in Children and Infants With Atopic Dermatitis Difamilast Phase 3 Not yet recruiting Otsuka Pharmaceutical Co., Ltd. Sep 22, 2025 A Phase 3 Trial to Demonstrate the Superiority of 1% OPA-15406 Foam to the Vehicle in Adult Patients With Atopic Dermatitis Difamilast Phase 3 Not yet recruiting Otsuka Pharmaceutical Co., Ltd. Sep 15, 2025 Efficacy and Safety Study of Dovramilast in People With Leprosy Type 2 Reaction Dovramilast Phase 2 Recruiting Medicines Development for Global Health Sep 15, 2025 Crisaborole 2% Versus Tacrolimus 0.1% in Children With Mild to Moderate Atopic Dermatitis Crisaborole Phase 3 Not yet recruiting Shalamar Institute of Health Sciences Sep 9, 2025 A Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasis Ensifentrine Phase 2 Recruiting Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA Aug 19, 2024 Ibudilast for Treating Alcohol Use Disorder Ibudilast Phase 2 Active, not recruiting University of Pennsylvania Jun 10, 2022 Effect of Ensifentrine (MK-5884/RPL554) on Sputum Markers of Inflammation in Chronic Obstructive Pulmonary Disease (COPD) (MK-5884-023/RPL554-CO-207) Ensifentrine Phase 2 Active, not recruiting Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA Mar 8, 2022 Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS Ibudilast Phase 2 / Phase 3 Active, not recruiting MediciNova Aug 15, 2019 DILIN - Prospective Study Dyphylline — Recruiting Duke University Jun 29, 2006
Show all 33Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2093863 , ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov , checked daily; this page as of 2026-11-21. ChEMBL and Open Targets